NovoCure Limited - Ordinary Shares (NQ:NVCR)

13.15 +0.04 (+0.31%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

NovoCure Q3 Earnings Call Highlights ↗

October 29, 2026

NovoCure (NASDAQ:NVCR) reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped...

Via MarketBeat

Topics Earnings

NovoCure (NVCR) Q3 2026 Earnings Call Transcript ↗

October 29, 2026

Record revenue and positive adjusted EBITDA in four years mark profitability shift.

Via The Motley Fool

Topics Earnings

Novocure (NASDAQ:NVCR) Q3 Results Beat Estimates as Raised Outlook Lifts Stock ↗

October 29, 2026

Via Chartmill

Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance

October 29, 2026

From Novocure

Via Business Wire

Novocure (NASDAQ:NVCR) Rallies 13% on Earnings Beat as High Growth Stock Nears Profitability ↗

July 23, 2026

Via Chartmill

Topics Earnings

Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement

October 28, 2026

From Novocure

Via Business Wire

Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

October 01, 2026

From Novocure

Via Business Wire

Novocure to Report Third Quarter 2026 Financial Results

October 01, 2026

From Novocure

Via Business Wire

NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even ↗

September 18, 2026

NovoCure (NASDAQ:NVCR) outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan...

Via MarketBeat

Novocure Announces Upcoming Investor Events

September 02, 2026

From Novocure

Via Business Wire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 23, 2026

Gainers NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regular session. The market value of their outstanding shares is at $1.8 billion. The company's, Q2 earnings...

Via Benzinga

The market is filled with gapping stocks in Thursday's session. ↗

July 23, 2026

Via Chartmill

Transcript: NovoCure Q2 2026 Earnings Conference Call ↗

July 23, 2026

NovoCure (NASDAQ:NVCR) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For...

Via Benzinga

Topics Earnings

NovoCure Q2 Earnings Call Highlights ↗

July 23, 2026

NovoCure (NASDAQ:NVCR) reported record second-quarter 2026 net revenue and active patient levels, with management pointing to growth across its approved products and improved expense discipline as it...

Via MarketBeat

Topics Earnings

Novocure Reports Second Quarter 2026 Financial Results

July 23, 2026

From Novocure

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

July 14, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

July 07, 2026

From Pomerantz LLP

Via GlobeNewswire

Novocure to Report Second Quarter 2026 Financial Results

July 01, 2026

From Novocure

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

June 30, 2026

From Pomerantz LLP

Via GlobeNewswire

Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer

June 30, 2026

From Novocure

Via Business Wire

HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026? ↗

June 24, 2026

AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.

Via The Motley Fool

Topics Artificial Intelligence

NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? ↗

June 22, 2026

Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.

Via The Motley Fool

NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm

June 20, 2026

From The Schall Law Firm

Via Business Wire

Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? ↗

June 19, 2026

Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.

Via The Motley Fool

Thursday's session: gap up and gap down stocks ↗

June 18, 2026

Via Chartmill

These stocks that are showing activity before the opening bell on Thursday. ↗

June 18, 2026

Via Chartmill

Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma

June 18, 2026

From Novocure

Via Business Wire

CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing ↗

June 09, 2026

This oncology device innovator, known for its tumor-treating technologies, reported a notable insider sale in its latest SEC filing.

Via The Motley Fool

Topics Regulatory Compliance

Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗

May 30, 2026

Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.

Via The Motley Fool

Topics Regulatory Compliance

3 Overlooked Stocks Set to Soar in 2026 ↗

May 05, 2026

These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.